NACDS’ Congressional statement keys on lowering patients’ costs at pharmacy counter, reducing overall healthcare costs, and fostering pharmacy viability by preventing below-cost reimbursement.
Morning Consult today published an opinion piece by the NACDS entitled “DIR Fee Reform: Lining Up Another Win for Patients on Drug Costs.”
NACDS today submitted a statement to the U.S. House of Representatives Committee on Ways and Means for the hearing titled “The Cost of Rising Prescription Drug Prices.”
NACDS and the National Community Pharmacists Association (NCPA) today lauded 24 patient and consumer groups for advocating for pharmacy direct and indirect remuneration (DIR) fee reform.
The National Community Pharmacists Association, the National Association of Chain Drug Stores, and the National Association of Specialty Pharmacy issued a statement regarding the Centers for Medicare & Medicaid Services’ release on Monday of the proposed rule titled “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses."
The legislation will prevent restrictions on pharmacists’ ability to tell patients when they can save money on prescriptions by paying cash instead of using insurance. Meanwhile, NACDS positions DIR fee reform as another crucial issue for lowering out-of-pocket drug costs.
The Patient Right to Know Drug Prices Act (S. 2554) is part of the effort to empower pharmacists to help patients lower out-of-pocket drug costs.
The bills would make it easier for Medicare patients to save money on prescription drugs.
NACDS has submitted comments to Health and Human Services Secretary Alex Azar in response to the agency’s request-for-information on drug-pricing public policy issues.